19.

20.

21.

22.

23.

24.

fill the prescriptions. The Respondent replied that she was “not aware that she
was summarily suspended.”

On May 9, 2017, the Board issued to Pharmacy A a subpoena for “copies of any
and all prescriptions written by Janet L. Wasson, M.D., DEA Number { ], from
April 25, 2017 to the present.”

In response to the Board's subpoena, Pharmacy A produced a “Doctor Drug
Monitoring Report” that revealed that the Respondent had written and authorized
a total of 11 prescriptions for two patients on May 8 and May 9, 2017. The
majority of the prescriptions were for opioids.

On May 10, 2017, the Board received a complaint from a pharmacist
(“Pharmacist B") employed at Pharmacy B, a large chain pharmacy. Pharmacist
B alleged that on or about May 6, 2017, the Respondent had electronically
transmitted to Pharmacy B a total of five prescriptions for two patients. The
prescriptions included oxycodone and morphine ER.

Board staff confirmed with Pharmacist B that the prescriptions were new and not
refills.

On May 11, 2017, the Board issued to Pharmacy B's parent company (“Company
A") a subpoena for “copies of any and all prescriptions written by Janet L.
Wasson, M.D. DEA Number [ ], from April 25, 2017 to the present.”

On May 15, 2017, Company A transmitted to the Board a Physician Activity
Report of the Respondent's prescriptions during the requested period. The
Respondent had written over 70 prescriptions, all of which were for scheduled

Controlled Dangerous Substances. The vast majority of the prescriptions were

9
